News for DexCom, Inc. (DXCM)

Shares of DexCom Inc (DXCM) fell 6.44% in mid-day trading on Mar 10. The stock reached an intraday low of $71.11, before recovering slightly to $72.83, down

U.S. equities continued their selloff on worries about the U.S economy possibly heading toward a recession.

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March

DexCom's growth is slowing with 2024 marking the slowest growth year in a decade and 2025 expected to follow suit with ~14% growth. Learn more on DXCM stock here.

DexCom, Inc. (NASDAQ:DXCM) 46th Annual Raymond James Institutional Investors Conference March 4, 2025 10:25 AM ETCompany ParticipantsJereme Sylvain - Chief...

Shares of DexCom Inc (DXCM) fell 3.67% in mid-day trading on Mar 4. The stock reached an intraday low of $81.77, before recovering slightly to $82.83, down

DexCom Inc (DXCM), a leader in glucose biosensing technology, announced that its management will present an update at the 46th Annual Raymond James Institutiona

[url="]DexCom, Inc.[/url] (NASDAQ:DXCM) today announced that management will present an update on the company at the 46th Annual Raymond James Institutional In

**media[552088]**

[url="]Tandem Diabetes Care, Inc.[/url] (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation au

AbbVie, Amgen, Stryker, Dexcom and Medtronic are included in this Analyst Blog.

PR NewswireBOSTON, Feb. 14, 2025 BOSTON, Feb. 14, 2025 /PRNewswire/ -- Below is the January 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc.

BOSTON, Feb. 14, 2025 /PRNewswire/ -- Below is the January 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG).

Financial giants have made a conspicuous bearish move on DexCom. Our analysis of options history for DexCom DXCM revealed 12 unusual trades. Delving into the d...

Shares of DexCom Inc (DXCM) surged 5.98% in mid-day trading on Feb 14. The stock reached an intraday high of $89.84, before settling at $89.12, up from its

DexCom, Inc. DXCM reported weaker-than-expected earnings for its fourth quarter on Thursday. The company posted quarterly earnings of 45 cents per share which ...

DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.

DXCM earnings call for the period ending December 31, 2024.

DexCom, Inc. reports solid Q4 2024 growth with record customer adds and innovative product launches.